MA48936B1 - Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques - Google Patents

Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques

Info

Publication number
MA48936B1
MA48936B1 MA48936A MA48936A MA48936B1 MA 48936 B1 MA48936 B1 MA 48936B1 MA 48936 A MA48936 A MA 48936A MA 48936 A MA48936 A MA 48936A MA 48936 B1 MA48936 B1 MA 48936B1
Authority
MA
Morocco
Prior art keywords
ester
vitamin
formulation based
treat bacterial
fungal biofilms
Prior art date
Application number
MA48936A
Other languages
English (en)
Other versions
MA48936A (fr
Inventor
Giorgio Panin
Original Assignee
Hulka S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hulka S R L filed Critical Hulka S R L
Publication of MA48936A publication Critical patent/MA48936A/fr
Publication of MA48936B1 publication Critical patent/MA48936B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une formulation à usage topique à base de vitamine e ou d'un ester de celle-ci, destinée à être utilisée en vue d'éliminer, de réduire ou d'inhiber un biofilm bactérien et/ou fongique, où ledit ester de vitamine e est un ester avec un acide carboxylique de formule r-cooh, dans laquelle r est un radical alkyle ayant de 1 à 19 atomes de carbone, ou un alcényle ou alcynyle ayant de 2 à 19 atomes de carbone.
MA48936A 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques MA48936B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
PCT/EP2018/063926 WO2018219862A1 (fr) 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques

Publications (2)

Publication Number Publication Date
MA48936A MA48936A (fr) 2020-04-08
MA48936B1 true MA48936B1 (fr) 2022-08-31

Family

ID=60294053

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48936A MA48936B1 (fr) 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques

Country Status (24)

Country Link
US (3) US20200360339A1 (fr)
EP (1) EP3630092B1 (fr)
CN (1) CN110650737A (fr)
AU (1) AU2018275487B2 (fr)
BR (1) BR112019023962A8 (fr)
CA (1) CA3061568C (fr)
CL (1) CL2019003254A1 (fr)
CY (1) CY1125414T1 (fr)
DK (1) DK3630092T3 (fr)
EA (1) EA201992190A1 (fr)
ES (1) ES2919423T3 (fr)
GE (2) GEP20207179B (fr)
HR (1) HRP20220808T1 (fr)
HU (1) HUE059185T2 (fr)
IT (1) IT201700058311A1 (fr)
LT (1) LT3630092T (fr)
MA (1) MA48936B1 (fr)
MX (1) MX389883B (fr)
PL (1) PL3630092T3 (fr)
PT (1) PT3630092T (fr)
RS (1) RS63347B1 (fr)
SI (1) SI3630092T1 (fr)
SM (1) SMT202200274T1 (fr)
WO (1) WO2018219862A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
CN116234544B (zh) * 2020-05-11 2025-09-19 勒芬天主教大学 二羧酸和三羧酸脂肪酸在预防生物膜形成中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
JPH09169643A (ja) * 1995-12-22 1997-06-30 Sekisui Chem Co Ltd 寄生性皮膚疾患治療用外用剤
IT1302275B1 (it) * 1998-09-25 2000-09-05 Giorgio Panin Formulazione di gel idrofobo a base di vitamina e acetato perapplicazione topica.
EP3406244B1 (fr) * 2009-04-15 2023-06-07 BMG Pharma S.p.A. Compositions comprenant du gluconate de zinc et de la taurine pour les troubles muqueux ou dermiques
ITUB20153889A1 (it) * 2015-09-25 2017-03-25 Bio Lo Ga Srl Gel idrofobico a base di vitamina E esente da prodotti siliconici per applicazione topica
ITUB20169882A1 (it) * 2016-01-08 2017-07-08 Flame S R L Vitamina E per l’uso nel trattamento e nella prevenzione delle infezioni da biofilm.
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Also Published As

Publication number Publication date
GEAP201815201A (fr) 2020-07-27
SI3630092T1 (sl) 2022-08-31
HRP20220808T1 (hr) 2022-09-30
US20200360339A1 (en) 2020-11-19
US11234958B2 (en) 2022-02-01
CY1125414T1 (el) 2025-05-09
IT201700058311A1 (it) 2018-11-29
SMT202200274T1 (it) 2022-07-21
MX389883B (es) 2025-03-20
EA201992190A1 (ru) 2020-09-03
WO2018219862A1 (fr) 2018-12-06
GEAP202015201A (en) 2020-07-27
PT3630092T (pt) 2022-06-02
CN110650737A (zh) 2020-01-03
PL3630092T3 (pl) 2022-09-12
US20210228541A1 (en) 2021-07-29
AU2018275487A1 (en) 2019-11-07
CL2019003254A1 (es) 2020-07-03
BR112019023962A8 (pt) 2022-07-05
BR112019023962A2 (pt) 2020-06-09
MA48936A (fr) 2020-04-08
DK3630092T3 (da) 2022-06-20
US20200121638A1 (en) 2020-04-23
ES2919423T3 (es) 2022-07-26
MX2019013559A (es) 2022-02-03
CA3061568A1 (fr) 2018-12-06
CA3061568C (fr) 2024-02-13
GEP20207179B (en) 2020-11-10
LT3630092T (lt) 2022-06-27
EP3630092B1 (fr) 2022-04-13
RS63347B1 (sr) 2022-07-29
HUE059185T2 (hu) 2022-10-28
AU2018275487B2 (en) 2024-03-14
EP3630092A1 (fr) 2020-04-08

Similar Documents

Publication Publication Date Title
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
PH12021550328A1 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
MX2016016993A (es) Compuestos de heteroarilo utiles como inhibidores de enzima activadora de sumo.
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
TN2011000659A1 (fr) Formulation pharmaceutique
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MA34359B1 (fr) Dérivés de carbamate d'hexafluoroisopropyle, leur préparation et leur application thérapeutique
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
MA48936B1 (fr) Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques
MA32798B1 (fr) Acides naphtylacétiques
MA38275B1 (fr) Hétérocycles azotés saturés et n-acylés potentialisant l'activité d'un antibiotique actif contre les mycobactéries
MX2021009252A (es) Uso de un agonista de ppar-delta en el tratamiento de trastornos de oxidacion de acidos grasos (faod).
MY197561A (en) Composition for increasing expression of pgc-1?
UY37856A (es) Mezclas inhibidoras de protoporfirinógeno oxidasas
EP3868385A4 (fr) Composition de traitement du cancer gastrique comprenant un inhibiteur de syt11 en tant qu'ingrédient actif
MX385971B (es) Compuesto de griseofulvina.
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA35134B1 (fr) Derives de pyrazolidinz-3-one
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA200800777A1 (ru) Применение сложных эфиров молочной кислоты для улучшения действия пестицидов
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
MA36538B1 (fr) Utilisation de composition a base d'extraits de microalgues marines pour le traitement d'acne
PH12021551103A1 (en) 1,3,4-oxadiazolone compound and medicine
MA38699A1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires